These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 26751497)

  • 1. Liposomal Coencapsulation of Doxorubicin with Listeriolysin O Increases Potency via Subcellular Targeting.
    Walls ZF; Gong H; Wilson RJ
    Mol Pharm; 2016 Mar; 13(3):1185-90. PubMed ID: 26751497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer.
    Deshpande P; Jhaveri A; Pattni B; Biswas S; Torchilin V
    Drug Deliv; 2018 Nov; 25(1):517-532. PubMed ID: 29433357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutants of listeriolysin O for enhanced liposomal delivery of macromolecules.
    Walls ZF; Goodell S; Andrews CD; Mathis J; Lee KD
    J Biotechnol; 2013 Apr; 164(4):500-2. PubMed ID: 23416330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Listeriolysin O enhances cytoplasmic delivery by Her-2 targeting liposomes.
    Kullberg M; Owens JL; Mann K
    J Drug Target; 2010 May; 18(4):313-20. PubMed ID: 20201742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposomal nitrooxy-doxorubicin: one step over caelyx in drug-resistant human cancer cells.
    Pedrini I; Gazzano E; Chegaev K; Rolando B; Marengo A; Kopecka J; Fruttero R; Ghigo D; Arpicco S; Riganti C
    Mol Pharm; 2014 Sep; 11(9):3068-79. PubMed ID: 25057799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced plasmid DNA delivery using anionic LPDII by listeriolysin O incorporation.
    Lorenzi GL; Lee KD
    J Gene Med; 2005 Aug; 7(8):1077-85. PubMed ID: 15776501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced Cytotoxicity of Folic Acid-Targeted Liposomes Co-Loaded with C6 Ceramide and Doxorubicin: In Vitro Evaluation on HeLa, A2780-ADR, and H69-AR Cells.
    Sriraman SK; Pan J; Sarisozen C; Luther E; Torchilin V
    Mol Pharm; 2016 Feb; 13(2):428-37. PubMed ID: 26702994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumor effect via passive anti-angiogenesis of PEGylated liposomes encapsulating doxorubicin in drug resistant tumors.
    Kibria G; Hatakeyama H; Sato Y; Harashima H
    Int J Pharm; 2016 Jul; 509(1-2):178-187. PubMed ID: 27234700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegylated liposomal doxorubicin in ovarian cancer.
    Green AE; Rose PG
    Int J Nanomedicine; 2006; 1(3):229-39. PubMed ID: 17717964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and characterization of novel recombinant listeriolysin O-protamine fusion proteins for enhanced gene delivery.
    Kim NH; Provoda C; Lee KD
    Mol Pharm; 2015 Feb; 12(2):342-50. PubMed ID: 25521817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sterol and pH interdependence in the binding, oligomerization, and pore formation of Listeriolysin O.
    Bavdek A; Gekara NO; Priselac D; Gutiérrez Aguirre I; Darji A; Chakraborty T; Macek P; Lakey JH; Weiss S; Anderluh G
    Biochemistry; 2007 Apr; 46(14):4425-37. PubMed ID: 17358050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human lymphocytic B-leukemia cell line treatment with the bacterial toxin listeriolysin O and rituximab (anti-CD20 antibody): Effects of similar localization of their receptors.
    Gryzik M; Grzywocz Z; Wasilewska D; Kawiak J; Stachowiak R; Bielecki J; Hoser G
    Int J Immunopathol Pharmacol; 2015 Sep; 28(3):329-40. PubMed ID: 26216910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential cytosolic delivery and presentation of antigen by listeriolysin O-liposomes to macrophages and dendritic cells.
    Stier EM; Mandal M; Lee KD
    Mol Pharm; 2005; 2(1):74-82. PubMed ID: 15804180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlated protein conformational states and membrane dynamics during attack by pore-forming toxins.
    Ponmalar II; Cheerla R; Ayappa KG; Basu JK
    Proc Natl Acad Sci U S A; 2019 Jun; 116(26):12839-12844. PubMed ID: 31189600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crystal structure of listeriolysin O reveals molecular details of oligomerization and pore formation.
    Köster S; van Pee K; Hudel M; Leustik M; Rhinow D; Kühlbrandt W; Chakraborty T; Yildiz Ö
    Nat Commun; 2014 Apr; 5():3690. PubMed ID: 24751541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.
    Rose PG; Smrekar M; Haba P; Fusco N; Rodriguez M
    Am J Clin Oncol; 2008 Oct; 31(5):476-80. PubMed ID: 18838885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous active intracellular delivery of doxorubicin and C6-ceramide shifts the additive/antagonistic drug interaction of non-encapsulated combination.
    Fonseca NA; Gomes-da-Silva LC; Moura V; Simões S; Moreira JN
    J Control Release; 2014 Dec; 196():122-31. PubMed ID: 25305563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific targeting of a pore-forming toxin (listeriolysin O) to LHRH-positive cancer cells using LHRH targeting peptide.
    Kheirandish MH; Jaliani HZ; Rahmani B; Nikukar H
    Toxicon; 2019 Jun; 164():82-86. PubMed ID: 30991063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells.
    Riganti C; Voena C; Kopecka J; Corsetto PA; Montorfano G; Enrico E; Costamagna C; Rizzo AM; Ghigo D; Bosia A
    Mol Pharm; 2011 Jun; 8(3):683-700. PubMed ID: 21491921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Listeriolysin O: a phagosome-specific lysin.
    Schnupf P; Portnoy DA
    Microbes Infect; 2007 Aug; 9(10):1176-87. PubMed ID: 17720603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.